Association between PD‐L1 expression and lymph node metastasis in cutaneous squamous cell carcinoma

Kamiya, Shiori; Kato, Junji; Kamiya, Takafumi; Yamashita, Toshiharu; Sumikawa, Yasuyuki; Hida, Tokimasa; Sato, Sayuri; Takahashi, Hitomi; Sawada, Masahide; Kubo, Terufumi; Torigoe, Toshihiko; Uhara, Hisashi

doi:10.1111/ajco.13102

Cited by 17 publications

(17 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In reported studies, 20%–70% of the patients with SCC had PD-L1 expression in tumor cells. [ 7 8 9 10 11 12 13 ] In the present study, 52.5% of the patients had PD-L1 expression in tumor cells. Although the expression of PD-L1 in sun-exposed skin and that in nonsun-exposed skin were evaluated in some previous studies, no statistically significant difference was found.…”

Section: Discussionsupporting

confidence: 47%

“…Although the expression of PD-L1 in sun-exposed skin and that in nonsun-exposed skin were evaluated in some previous studies, no statistically significant difference was found. [ 12 13 ] However, the number of patients with SCC in nonsun-exposed skin in those studies was relatively small. [ 12 13 ] In our study, a significant correlation was found between sun exposure and expression of PD-L1 in tumor cells.…”

Section: Discussionmentioning

confidence: 99%

“…[ 12 13 ] However, the number of patients with SCC in nonsun-exposed skin in those studies was relatively small. [ 12 13 ] In our study, a significant correlation was found between sun exposure and expression of PD-L1 in tumor cells. According to a previous study, SCC has a high mutation burden because of the damage caused by UV light.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Expression of programmed death-ligand 1 in cutaneous squamous cell carcinoma arising in sun-exposed and nonsun-exposed skin

2020

View full text Add to dashboard Cite

Background: A recent clinical trial has shown the efficacy of an anti-programmed death-1 (PD-1) antibody against advanced squamous cell carcinoma (SCC). The expression of PD-ligand 1 (PD-L1) in tumor cells correlates with a favorable response to anti-PD-1 therapy in various malignancies. In recent studies, it has been shown that SCC frequently expresses PD-L1. However, there has been no previous study focusing on the difference in PD-L1 expression between SCC in sun-exposed skin and that in nonsun-exposed areas. Aims: The purpose of this study was to investigate the relationship between sun-exposure status and PD-L1 expression in patients with SCC. Materials and Methods: We investigated 80 patients with SCC (40 patients with SCC in sun-exposed skin and 40 patients with SCC in nonsun-exposed skin) by immunohistochemical staining for PD-L1. Fisher's exact test was used for statistical analyses of the differences between the two groups. Results: Patients with SCC in sun-exposed skin showed a significantly higher expression level of PD-L1 in tumor cells than did patients with SCC in nonsun-exposed skin ( P = 0.0133). Conclusions: We found that the expression level of PD-L1 in patients with SCC in sun-exposed skin was higher than in patients with SCC in nonsun-exposed skin. Practical data are needed for appropriate applications of new therapeutic options for SCC.

show abstract

Section: Discussionsupporting

confidence: 47%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Expression of programmed death-ligand 1 in cutaneous squamous cell carcinoma arising in sun-exposed and nonsun-exposed skin

2020

View full text Add to dashboard Cite

show abstract

“…Whether this reflects effects of altered microenvironment and/or evasion of immune surveillance is unclear. Kamiya et al73 found that a higher intensity of PD-L1 staining, but not the proportion of tumor cells with PD-L1 staining, correlated with nodal metastasis in cutaneous SCC. In contrast, Garcia-Pedrero et al74 found that PD-L1 expression in more than 25% of tumor cells correlated with lymph node metastasis in head and neck cutaneous SCC.…”

Section: Discussionmentioning

confidence: 99%

PD-L1/PD1 Expression, Composition of Tumor-Associated Immune Infiltrate, and HPV Status in Conjunctival Squamous Cell Carcinoma

Nagarajan

El-Hadad

Gruschkus

et al. 2019

Invest. Ophthalmol. Vis. Sci.

View full text Add to dashboard Cite

PURPOSE. Conjunctival squamous cell carcinoma (SCC), a type of ocular surface neoplasia, is primarily treated by surgical resection and topical immuno-or chemotherapy. Metastatic disease may be treated with systemic chemo-or immunotherapy, albeit with variable response. The purpose of this study was to determine whether immune checkpoint blockade might be considered in the management of conjunctival SCC. METHODS. In this retrospective study, we evaluated tumor programmed death-ligand 1 (PD-L1) expression, high-risk human papillomavirus (HPV) status, and immunohistochemical expression of cluster of differentiation 3 (CD3), cluster of differentiation 8 (CD8), and programmed death 1 (PD1) in tumor-associated immune infiltrate in a series of 31 conjunctival SCCs. RESULTS. PD-L1 expression in ‡1% of tumor cells was noted in 14 conjunctival SCCs (47%) and was more prevalent in invasive than in situ SCC and among tumors with higher American Joint Committee on Cancer (AJCC) T category (‡T3 versus T2). The density of CD3-positive T cells was higher in primary than recurrent tumors and higher in invasive than in situ tumors. Density of CD3-positive and CD8-positive T cells was higher in higher AJCC stage tumors. Density of CD8-positive T cells was higher in HPV-positive than HPV-negative tumors. PD-L1 expression correlated with a higher density of CD3-, CD8-, and PD1-positive cells in the tumor-associated immune infiltrate but not with HPV status. CONCLUSIONS. Our findings demonstrate that PD-L1 is expressed in almost half of conjunctival SCCs. The density of tumor-associated immune cells correlated with invasive SCC, stage, and HPV status in conjunctival SCC. Our findings support further studies to establish the potential application of immune checkpoint blockade in the management of conjunctival SCC.

show abstract

“…metastatic cSCC, it has not been reported whether response is related to PD-L1 expression status [5,[42][43][44].…”

Section: Pd-l1 Expressionmentioning

confidence: 99%

Driving innovation for rare skin cancers: utilizing common tumours and machine learning to predict immune checkpoint inhibitor response

Hooiveld-Noeken

Fehrmann

Vries

et al. 2019

Immuno-Oncology Technology

View full text Add to dashboard Cite

Metastatic Merkel cell carcinoma (MCC) and cutaneous squamous cell carcinoma (cSCC) are rare and both show impressive responses to immune checkpoint inhibitor treatment. However, at least 40% of patients do not respond to these expensive and potentially toxic drugs. Development of predictive biomarkers of response and rational, effective combination treatment strategies in these rare, often frail patient populations is challenging. This review discusses the pathophysiology and treatment of MCC and cSCC, with a particular focus on potential biomarkers of response to immunotherapy, and discusses how transfer learning using big data collected from patients with common tumours can be used in combination with deep phenotyping of rare tumours to develop predictive biomarkers and elucidate novel treatment targets.

show abstract

Association between PD‐L1 expression and lymph node metastasis in cutaneous squamous cell carcinoma

Cited by 17 publications

References 19 publications

Expression of programmed death-ligand 1 in cutaneous squamous cell carcinoma arising in sun-exposed and nonsun-exposed skin

Expression of programmed death-ligand 1 in cutaneous squamous cell carcinoma arising in sun-exposed and nonsun-exposed skin

PD-L1/PD1 Expression, Composition of Tumor-Associated Immune Infiltrate, and HPV Status in Conjunctival Squamous Cell Carcinoma

Driving innovation for rare skin cancers: utilizing common tumours and machine learning to predict immune checkpoint inhibitor response

Contact Info

Product

Resources

About